This whitepaper explores how pharmaceutical companies can unlock the true value of AI by building connected, multi-enterprise supply chain networks instead of relying on siloed enterprise systems. It explains how fragmented data, static lead times, and disconnected ecosystems limit AI’s ability to improve decision-making, resilience, and operational efficiency. The paper highlights the importance of real-time network data, shared data models, and ecosystem-wide collaboration to support advanced AI use cases such as predictive batch failure analysis, multi-tier constrained supply planning, personalized medicine logistics, cold chain optimization, and risk management. Blue Yonder emphasizes that network-based AI enables pharmaceutical brands, manufacturers, and logistics partners to optimize

Join for free to read